Dasatinib was ineffective in phase I/II trials in recurrent GB, even in combination with bevacizumab or lomustine, which could be due to a proposed active efflux mechanism [224,402,404,406]; however, efficacy of dasatinib treatment of PDGFRα-driven high grade gliomas could be enhanced with everolimus [407]. The gene discussed is PDGFRA; the disease is central nervous system cancer.